Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis.

Nai A, Pettinato M, Federico G, Olivari V, Carlomagno F, Silvestri L.

Haematologica. 2019 Aug;104(8):e383-e384. doi: 10.3324/haematol.2019.224857. No abstract available.

2.

Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition.

Sottile R, Federico G, Garofalo C, Tallerico R, Faniello MC, Quaresima B, Cristiani CM, Di Sanzo M, Cuda G, Ventura V, Wagner AK, Contrò G, Perrotti N, Gulletta E, Ferrone S, Kärre K, Costanzo FS, Carlomagno F, Carbone E.

Front Immunol. 2019 Feb 26;10:224. doi: 10.3389/fimmu.2019.00224. eCollection 2019.

3.

Association between DNA methylation profile and malignancy in follicular-patterned thyroid neoplasms.

Affinito O, Salerno P, D'Alessio AM, Cuomo M, Florio E, Carlomagno F, Proietti A, Giannini R, Basolo F, Chiariotti L, Cocozza S, Santoro M.

Endocr Relat Cancer. 2019 Apr 1;26(4):451-462. doi: 10.1530/ERC-18-0308. Epub 2019 Feb 1.

PMID:
30753136
4.

Retraction: The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins.

Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A.

Cancer Res. 2018 Dec 15;78(24):6907. doi: 10.1158/0008-5472.CAN-18-3456. No abstract available.

PMID:
30552125
5.

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.

Yan W, Lakkaniga NR, Carlomagno F, Santoro M, McDonald NQ, Lv F, Gunaganti N, Frett B, Li HY.

J Med Chem. 2019 Feb 28;62(4):1731-1760. doi: 10.1021/acs.jmedchem.8b01092. Epub 2018 Sep 19.

PMID:
30188734
6.

Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome.

Tahani N, Nieddu L, Prossomariti G, Spaziani M, Granato S, Carlomagno F, Anzuini A, Lenzi A, Radicioni AF, Romagnoli E.

Endocrine. 2018 Aug;61(2):327-335. doi: 10.1007/s12020-018-1604-6. Epub 2018 Apr 25.

PMID:
29696556
7.

The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

De Falco V, Carlomagno F, Li HY, Santoro M.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):307-318. doi: 10.1016/j.beem.2017.04.013. Epub 2017 May 10. Review.

8.

Clinical Improvement of Subacute and Chronic Otitis Media With Effusion Treated With Hyaluronic Acid Plus Hypertonic Solution via Nasal Lavage: A Randomized Controlled Trial.

Cioffi L, Gallo P, D'Avino A, Carlomagno F, Aloi G, D'Onofrio A, Del Gaizo D, Giuliano M, De Franchis R, Sandomenico ML, Pecoraro A.

Glob Pediatr Health. 2017 Sep 1;4:2333794X17725983. doi: 10.1177/2333794X17725983. eCollection 2017.

9.

Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis.

Matte A, De Falco L, Federti E, Cozzi A, Iolascon A, Levi S, Mohandas N, Zamo A, Bruno M, Lebouef C, Janin A, Siciliano A, Ganz T, Federico G, Carlomagno F, Mueller S, Silva I, Carbone C, Melisi D, Kim DW, Choi SY, De Franceschi L.

Antioxid Redox Signal. 2018 Jan 1;28(1):1-14. doi: 10.1089/ars.2017.7051. Epub 2017 Sep 6.

PMID:
28793778
10.

Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess.

Pivonello R, De Martino MC, Iacuaniello D, Simeoli C, Muscogiuri G, Carlomagno F, De Leo M, Cozzolino A, Colao A.

Front Horm Res. 2016;46:54-65. doi: 10.1159/000443864. Epub 2016 May 17. Review.

PMID:
27212264
11.

NCOA4 Deficiency Impairs Systemic Iron Homeostasis.

Bellelli R, Federico G, Matte' A, Colecchia D, Iolascon A, Chiariello M, Santoro M, De Franceschi L, Carlomagno F.

Cell Rep. 2016 Jan 26;14(3):411-421. doi: 10.1016/j.celrep.2015.12.065. Epub 2016 Jan 14.

12.

Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.

Frett B, Carlomagno F, Moccia ML, Brescia A, Federico G, De Falco V, Admire B, Chen Z, Qi W, Santoro M, Li HY.

Angew Chem Int Ed Engl. 2015 Jul 20;54(30):8717-21. doi: 10.1002/anie.201501104. Epub 2015 Jun 30.

13.

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.

Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M.

PLoS One. 2015 Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364. eCollection 2015.

14.

Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

Frett B, Moccia M, Carlomagno F, Santoro M, Li HY.

Eur J Med Chem. 2014 Oct 30;86:714-23. doi: 10.1016/j.ejmech.2014.09.023. Epub 2014 Sep 8.

15.

NCOA4 transcriptional coactivator inhibits activation of DNA replication origins.

Bellelli R, Castellone MD, Guida T, Limongello R, Dathan NA, Merolla F, Cirafici AM, Affuso A, Masai H, Costanzo V, Grieco D, Fusco A, Santoro M, Carlomagno F.

Mol Cell. 2014 Jul 3;55(1):123-37. doi: 10.1016/j.molcel.2014.04.031. Epub 2014 Jun 5.

16.

Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy.

Carlomagno F, Chiariello M.

J Mol Med (Berl). 2014 Jul;92(7):723-33. doi: 10.1007/s00109-014-1177-7. Epub 2014 Jun 8. Review.

PMID:
24906458
17.

Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.

Bossi D, Carlomagno F, Pallavicini I, Pruneri G, Trubia M, Raviele PR, Marinelli A, Anaganti S, Cox MC, Viale G, Santoro M, Di Fiore PP, Minucci S.

Mol Oncol. 2014 Mar;8(2):221-31. doi: 10.1016/j.molonc.2013.11.004. Epub 2013 Nov 19.

18.

Central role of RET in thyroid cancer.

Santoro M, Carlomagno F.

Cold Spring Harb Perspect Biol. 2013 Dec 1;5(12):a009233. doi: 10.1101/cshperspect.a009233. Review.

19.

Oncogenic rearrangements driving ionizing radiation-associated human cancer.

Santoro M, Carlomagno F.

J Clin Invest. 2013 Nov;123(11):4566-8. doi: 10.1172/JCI72725. Epub 2013 Oct 25.

20.

Attacking cancer with molecularly targeted agents.

Santoro M, Carlomagno F.

Curr Opin Pharmacol. 2013 Aug;13(4):483-5. doi: 10.1016/j.coph.2013.06.011. Epub 2013 Jul 16. No abstract available.

PMID:
23871444
21.

Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.

Krishnamoorthy GP, Guida T, Alfano L, Avilla E, Santoro M, Carlomagno F, Melillo RM.

J Biol Chem. 2013 Jun 14;288(24):17481-94. doi: 10.1074/jbc.M112.439422. Epub 2013 Apr 29.

22.

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.

De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.

PMID:
23526464
23.

Structure prediction and validation of the ERK8 kinase domain.

Strambi A, Mori M, Rossi M, Colecchia D, Manetti F, Carlomagno F, Botta M, Chiariello M.

PLoS One. 2013;8(1):e52011. doi: 10.1371/journal.pone.0052011. Epub 2013 Jan 11.

24.

Thyroid Cancer: Role of RET and Beyond.

Carlomagno F.

Eur Thyroid J. 2012 Apr;1(1):15-23. doi: 10.1159/000336975. Epub 2012 Mar 28. Review.

25.

Thyroid cancer in 2010: a roadmap for targeted therapies.

Carlomagno F, Santoro M.

Nat Rev Endocrinol. 2011 Feb;7(2):65-7. doi: 10.1038/nrendo.2010.232. Review. No abstract available.

PMID:
21263433
26.

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M.

Endocr Relat Cancer. 2010 Nov 30;18(1):1-11. doi: 10.1677/ERC-09-0292. Print 2011 Feb.

PMID:
20943719
27.

RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.

Alfano L, Guida T, Provitera L, Vecchio G, Billaud M, Santoro M, Carlomagno F.

J Clin Endocrinol Metab. 2010 Jul;95(7):3552-7. doi: 10.1210/jc.2009-2315. Epub 2010 May 5.

PMID:
20444924
28.

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.

Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M.

Cancer Res. 2009 Mar 1;69(5):1916-23. doi: 10.1158/0008-5472.CAN-08-1693. Epub 2009 Feb 17.

29.

Receptor tyrosine kinase inhibitors in thyroid cancer.

Castellone MD, Carlomagno F, Salvatore G, Santoro M.

Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1023-38. doi: 10.1016/j.beem.2008.09.012. Review.

PMID:
19041829
30.

Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.

Carlomagno F, Guida T, Anaganti S, Provitera L, Kjaer S, McDonald NQ, Ryan AJ, Santoro M.

Endocr Relat Cancer. 2009 Mar;16(1):233-41. doi: 10.1677/ERC-08-0213. Epub 2008 Nov 24.

PMID:
19029224
31.

Pros and cons of cellular studies in developing new drugs for thyroid cancers.

Salvatore G, Carlomagno F, Santoro M.

Thyroid. 2008 Aug;18(8):819-22. doi: 10.1089/thy.2008.1541. No abstract available.

PMID:
18690794
32.

New therapeutic approaches to treat medullary thyroid carcinoma.

Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M.

Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):22-32. Review.

PMID:
18084343
33.

Constitutive and AP20187-induced Ret activation in photoreceptors does not protect from light-induced damage.

Allocca M, Di Vicino U, Petrillo M, Carlomagno F, Domenici L, Auricchio A.

Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5199-206.

PMID:
17962474
34.

Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein.

Minopoli G, Passaro F, Aloia L, Carlomagno F, Melillo RM, Santoro M, Forzati F, Zambrano N, Russo T.

Neurodegener Dis. 2007;4(2-3):94-100.

PMID:
17596703
35.

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.

Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F.

Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

36.

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer.

Santoro M, Carlomagno F.

Nat Clin Pract Endocrinol Metab. 2006 Jan;2(1):42-52. Review.

PMID:
16932252
37.

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.

Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A.

Cancer Res. 2006 Jun 15;66(12):6280-7. Retraction in: Cancer Res. 2018 Dec 15;78(24):6907.

38.

BRAF is a therapeutic target in aggressive thyroid carcinoma.

Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.

Clin Cancer Res. 2006 Mar 1;12(5):1623-9.

39.

BAY 43-9006 inhibition of oncogenic RET mutants.

Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M.

J Natl Cancer Inst. 2006 Mar 1;98(5):326-34.

PMID:
16507829
40.

Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene.

Iavarone C, Acunzo M, Carlomagno F, Catania A, Melillo RM, Carlomagno SM, Santoro M, Chiariello M.

J Biol Chem. 2006 Apr 14;281(15):10567-76. Epub 2006 Feb 16.

41.

Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study.

Di Donato P, Giulini NA, Bacchi Modena A, Cicchetti G, Comitini G, Gentile G, Cristiani P, Careccia A, Esposito E, Gualdi F, Golinelli S, Bergamini E, Masellis G, Rastelli S, Gigli C, Elia A, Marchesoni D, Sticotti F, Del Frate G, Zompicchiatti C, Marino L, Costa MR, Pinto P, Dodero D, Storace A, Spinelli G, Quaranta S, Bossi CM, Ollago A, Omodei U, Vaccari M, Luerti M, Repetti F, Zandonini G, Raspagliesi F, Dolci F, Gambarino G, De Pasquale B, Polizzotti G, Borsellino G, Alpinelli P, Natale N, Colombo D, Belloni C, Viani A, Cecchini G, Vinci GW, Samaja BA, Pasinetti E, Penotti M, Ognissanti F, Pesando P, Malanetto C, Gallo M, Dolfin G, Tartaglino P, Mossotto D, Pistoni A, Tarani A, Rattazzi PD, Rossaro D, Campanella M, Arisi E, Gamper M, Salvatores D, Bocchin E, Stellin G, Meli G, Azzini V, Tirozzi F, Buoso G, Fraioli R, Marsoni V, Cetera C, Sposetti R, Candiotto E, Pignalosa R, Del Pup L, Bellati U, Angeloni C, Buonerba M, Garzarelli S, Santilli C, Mucci M, Di Nisio Q, Cappa F, Pierangeli I, Cordone A, Falasca L, Ferrante D, Serra GB, Cirese E, Todaro PA, Romanini C, Spagnuolo L, Lanzone A, Donadio C, Fabiani M, Baldaccini E, Votano S, Bellardini P, Favale W, Monti V, Bonomo A, Boninfante CE, Pietrobattista P, Massacesi L, Donini G, Del Savio F, Palombi L, Procaccioli P, Romani A, Romagnoli G, Genazzani AR, Gambacciani M, Scarselli G, Curiel P, De Leo V, Melani A, Levi D'Ancona V, Giarrè G, Di Gioia E, Ceccarelli P, Massi GB, Cosci S, Gacci G, Cascianini A, Donati Sarti C, Bircolotti S, Pupita P, Mincigrucci M, Spadafora A, Santeufemia G, Marongiu G, Lai GR, Lai R, Dessole S, D'Andrea SA, Coppola, Chiantera A, De Placido, Arienzo R, Pastore AR, Tamburrino A, Cardone A, Colacurci N, Izzo S, Tesauro R, Pascarella A, De Silvio MG, Di Prisco L, Lauda N, Sirimarco F, Agrimi C, Casarella G, Senatore G, Ronzini S, Ruccia G, De Carlo G, Pisaturo G, Carlomagno F, Fasolino A, Fiorillo F, Sorrentino R, Ercolano VB, Panariello S, Brun A, Tropea P, Stigliano CM, Amoroso A, Vadalà P, Coco A, Galati G, Barese G, Masciari G, Pirillo P, Gioffrè T, Mastrantonio P, Cardamone A, D'Angelo N, Valentino G, Barretta R, Ferraro G, Ferruccio C, Agostinelli D, Corrado G, Scopelliti A, Schonauer S, Trojano V, Bongiovanni F, Tinelli F, Poddi ER, Scarpello F, Colonna L, Fischetti G, Doria R, Trombetta G, Cocca EB, D'Amore A, Di Masi M, Liguori R, Dimaggio A, Laneve MR, Maolo MC, Gravina G, Nacci G, Nocera F, Lupo A, Giannola C, Graziano R, Mezzatesta M, Vegna G, Giannone G, Palumbo G, Cancellieri F, Mondo A, Cordopatri A, Carrubba M, Mazzola V, Cincotta L, D'Asta S, Bono A, Li Calsi L, Cavallaro Nigro S, Schilirò S, Repici A, Gullo D, Orlando A, Specchiale F, Papotto A, Abruzzo, Basilicata, Calabria, Campania, Emilia, Romagna, Giulia FV, Lazio, Liguria, Lombardia, Marche, Molise, Piemonte, Puglia, Sardegna, Sicilia, Toscana, Adige TA, Umbria, D'Aosta V, Veneto, Massacesi A, Chiantera A, Donati Sarti C, De Aloysio P, Omodei U, Ognissanti F, Campagnoli C, Penotti M, Gambacciani A, Graziottin A, Baldi C, Colacurci N, Corrado Tonti G, Parazzini F, Chatenoud L; Gruppo di Studio Progetto Menopausa Italia.

Climacteric. 2005 Sep;8(3):287-93.

PMID:
16397927
42.

Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.

D'Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, Filetti S.

J Clin Endocrinol Metab. 2006 Mar;91(3):754-9. Epub 2005 Dec 29.

PMID:
16384843
43.

Factors associated with climacteric symptoms in women around menopause attending menopause clinics in Italy.

Di Donato P, Giulini NA, Bacchi Modena A, Cicchetti G, Comitini G, Gentile G, Cristiani P, Careccia A, Esposito E, Gualdi F, Golinelli S, Bergamini E, Masellis G, Rastelli S, Gigli C, Elia A, Marchesoni D, Sticotti F, Del Frate G, Zompicchiatti C, Marino L, Costa MR, Pinto P, Dodero D, Storace A, Spinelli G, Quaranta S, Bossi CM, Ollago A, Omodei U, Vaccari M, Luerti M, Repetti F, Zandonini G, Raspagliesi F, Dolci F, Gambarino G, De Pasquale B, Polizzotti G, Borsellino G, Alpinelli P, Natale N, Colombo D, Belloni C, Viani A, Cecchini G, Vinci GW, Samaja BA, Pasinetti E, Penotti M, Ognissanti F, Pesando P, Malanetto C, Gallo M, Dolfin G, Tartaglino P, Mossotto D, Pistoni A, Tarani A, Rattazzi PD, Rossaro D, Campanella M, Arisi E, Gamper M, Salvatores D, Bocchin E, Stellin G, Meli G, Azzini V, Tirozzi F, Buoso G, Fraioli R, Marsoni V, Cetera C, Sposetti R, Candiotto E, Sposetti R, Candiotto E, Pignalosa R, Del Pup L, Bellati U, Angeloni C, Buonerba M, Garzarelli S, Santilli C, Mucci M, Di Nisio Q, Cappa F, Pierangeli I, Cordone A, Falasca L, Ferrante D, Cirese E, Todaro PA, Spagnuolo L, Lanzone A, Donadio C, Fabiani M, Baldaccini E, Votano S, Bellardini P, Favale W, Pietrobattista V, Massacesi L, Donini G, Del Savio F, Palombi L, Procaccioli P, Romani A, Romagnoli G, Genazzani AR, Gambacciani M, Scarselli G, Curiel P, De Leo V, Melani A, Levi D'Ancona V, Giarrè G, Di Gioia E, Ceccarelli P, Massi GB, Cosci S, Gacci G, Cascianini A, Donati Sarti C, Bircolotti S, Pupita P, Mincigrucci M, Spadafora A, Santeufemia G, Marongiu G, Lai GR, Lai R, Dessole S, D'Andrea SA, Coppola, Chiantera A, De Placido, Arienzo R, Pastore AR, Tamburrino A, Cardone A, Colacurci N, Izzo S, Tesauro R, Pascarella A, De Silvio MG, Di Prisco L, Lauda N, Sirimarco F, Agrimi C, Casarella G, Senatore G, Ronzini S, Ruccia G, De Carlo G, Pisaturo G, Carlomagno F, Fasolino A, Fiorillo F, Sorrentino R, Ercolano VB, Panariello S, Brun A, Tropea P, Stigliano CM, Amoroso A, Vadalà P, Coco A, Galati G, Barese G, Masciari G, Pirillo P, Gioffrè T, Mastrantonio P, Cardamone A, D'Angelo N, Valentino G, Barretta R, Ferraro G, Ferruccio C, Agostinelli D, Corrado G, Scopelliti A, Schonauer S, Trojano V, Bongiovanni F, Tinelli F, Poddi ER, Scarpello F, Colonna L, Fischetti G, Doria R, Trombetta G, Cocca EB, D'Amore A, Di Masi M, Liguori R, Dimaggio A, Laneve MR, Maolo MC, Gravina G, Nacci G, Nocera F, Lupo A, Giannola C, Graziano R, Mezzatesta M, Vegna G, Giannone G, Palumbo G, Cancellieri F, Mondo A, Cordopatri A, Carrubba M, Mazzola V, Cincotta L, D'Asta S, Bono A, Li Calsi L, Cavallaro Nigro S, Schilirò S, Repici A, Gullo D, Orlando A, Specchiale F, Papotto A, Angeloni, D'Andrea, Stigliano, Arienzo, Di Donato, Giulini, Gigli, Todaro, Marino, Luerti, Donini, Ferrante, Dolfin, Poddi, Santeufemia, Nocera, Melani, Arisi, Mincigrucci, Salvatores, Bocchin, Massacesi A, Chiantera A, De Aloysio P, Omodei U, Ognissanti F, Campagnoli C, Penotti M, Gambacciani A, Graziottin A, Baldi C, Colacurci N, Tonti GC, Parazzini F, Chatenoud L, Donati Sarti C; Progetto Menopausa Italia Study Group.

Maturitas. 2005 Nov-Dec;52(3-4):181-9.

PMID:
16257609
44.

Receptor tyrosine kinases as targets for anticancer therapeutics.

Carlomagno F, Santoro M.

Curr Med Chem. 2005;12(15):1773-81.

PMID:
16029146
45.

Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma.

Guida T, Salvatore G, Faviana P, Giannini R, Garcia-Rostan G, Provitera L, Basolo F, Fusco A, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2005 Aug;90(8):4703-9. Epub 2005 May 17.

PMID:
15899946
46.
47.

Dysfunction of the RET receptor in human cancer.

Santoro M, Carlomagno F, Melillo RM, Fusco A.

Cell Mol Life Sci. 2004 Dec;61(23):2954-64. Review.

PMID:
15583857
48.

Minireview: RET: normal and abnormal functions.

Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A.

Endocrinology. 2004 Dec;145(12):5448-51. Epub 2004 Aug 26. Review.

PMID:
15331579
49.

The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.

Melillo RM, Cirafici AM, De Falco V, Bellantoni M, Chiappetta G, Fusco A, Carlomagno F, Picascia A, Tramontano D, Tallini G, Santoro M.

Am J Pathol. 2004 Aug;165(2):511-21.

50.

Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.

Castellone MD, Guarino V, De Falco V, Carlomagno F, Basolo F, Faviana P, Kruhoffer M, Orntoft T, Russell JP, Rothstein JL, Fusco A, Santoro M, Melillo RM.

Oncogene. 2004 Aug 5;23(35):5958-67.

PMID:
15184868

Supplemental Content

Loading ...
Support Center